6-K
ASTRAZENECA PLC (AZN)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of August 2025
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1. Director/PDMR Shareholding
18 August 2025
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announces that, on 15 August 2025, it was notified of a transaction in the Company's ordinary shares of $0.25 each (Ordinary Shares), by Aradhana Sarin, Executive Director and Chief Financial Officer, on 14 August 2025, as set out below.
| PDMR | Position | Nature of the transaction | Quantity | Price per Ordinary Share |
|---|---|---|---|---|
| Aradhana Sarin | Executive Director and Chief Financial Officer | Sale of Ordinary Shares | 9563 | £115.117 |
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.
| 1 | Details of the person discharging managerial responsibilities /<br>person closely associated | |
|---|---|---|
| a) | Name | Aradhana Sarin |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |
| a) | Name | AstraZeneca PLC |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 |
| 4i | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted | |
| a) | Description of the financial instrument, type of<br>instrument<br><br><br><br><br><br>Identification code | Ordinary Shares of US0.25 each in AstraZeneca PLC<br><br><br> <br><br><br>GB0009895292 |
| b) | Nature of the transaction | Sale of Ordinary<br>Shares of US0.25 each in AstraZeneca PLC |
| c) | Price(s) and volume(s) | Price(s) |
| 115.117 | ||
| d) | Aggregated information<br><br><br><br><br><br>- Aggregated volume<br><br><br><br><br><br>- Price | Not applicable - single transaction |
| e) | Date of the transaction | 14 August 2025 |
| f) | Place of the transaction | LON |
All values are in US Dollars.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AstraZeneca<br>PLC |
|---|
Date: 18 August 2025
| By: /s/<br>Matthew Bowden |
|---|
| Name:<br>Matthew Bowden |
| Title:<br>Company Secretary |